1. CSF YWHAG:NPTX2 seems to be a robust prognostic biomarker for cognitive resilience vs Alzheimer's disease onset and progression.
2. YWHAG:NPTX2 predicts both conversion to mild cognitive impairment and dementia.
3. Synaptic proteins independently correlate with cognitive impairment, highlighting synapse dysfunction as a core driver of AD dementia.
4. CSF YWHAG:NPTX2 may aid in clinical trial target patient selection and therapeutic efficacy evaluation.
5. A plasma proteomic signature partially recapitulates CSF YWHAG:NPTX2, demonstrating potential scalability for clinical application.

Source: Nature Medicine